All questionsSpecific populations: Wegovy (semaglutide), all indications4 questions · 3 sourcesSpecific populationsCan Wegovy be used during pregnancy?“Based on animal reproduction studies, there may be potential risks to the fetus from exposure to semaglutide during pregnancy. Available pharmacovigilance data and data from clinical trials with WEGOVY® use in pregnant patients are insufficient to establish a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes.” (opens the source at this quote in a new tab)CopyFlag“Weight loss offers no benefit to a pregnant patient and may cause fetal harm. When a pregnancy is recognized, advise the pregnant patient of the risk to a fetus. Discontinue WEGOVY® in pregnant patients who are using it for weight reduction (see Clinical Considerations).” (opens the source at this quote in a new tab)CopyFlag“Disease-Associated Maternal and/or Embryo/fetal Risk: Appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those who already have overweight or obesity, because of the obligatory weight gain that occurs in maternal tissues during pregnancy.” (opens the source at this quote in a new tab)CopyFlag“There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to WEGOVY® during pregnancy. Pregnant women exposed to WEGOVY® and healthcare providers are encouraged to contact Novo Nordisk at 1-877-390-2760 or www.wegovypregnancyregistry.com.” (opens the source at this quote in a new tab)CopyFlagHow long before pregnancy should Wegovy be stopped?“Because of the potential for fetal harm, discontinue WEGOVY® in patients at least 2 months before they plan to become pregnant to account for the long half-life of semaglutide [see Use in Specific Populations (8.1)].” (opens the source at this quote in a new tab)CopyFlagCan Wegovy be used while breastfeeding?“Lactation: A clinical lactation study reported semaglutide concentrations below the lower limit of quantification in human breast milk. However, salcaprozate sodium (SNAC) and/or its metabolites are present in human milk. Because of the unknown potential for serious adverse reactions in the breastfed infant due to the possible accumulation of SNAC, an absorption enhancer for Wegovy® tablets, and because there are alternative formulations of semaglutide that do not contain SNAC that can be used during lactation, advise patients that breastfeeding is not recommended during treatment with Wegovy® tablets” (opens the source at this quote in a new tab)CopyFlag“WEGOVY® Subcutaneous Injection There are no data on the presence of subcutaneously administered semaglutide or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production. WEGOVY® subcutaneous injection does not contain the SNAC metabolites. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for WEGOVY® and any potential adverse effects on the breastfed infant from WEGOVY® or from the underlying maternal condition.” (opens the source at this quote in a new tab)CopyFlagNote: The first passage concerns Wegovy tablets and the second Wegovy injection.Can people with kidney or liver disease take Wegovy?“Age, Sex, Race, Ethnicity, Body Weight, and Other Intrinsic Factors: No clinically significant differences in semaglutide pharmacokinetics were observed based on age (<65 years, 65 to 74, ≥75 years old), sex, race (White, Asian, or Black or African American), ethnicity, body weight, upper GI disease (i.e. chronic gastritis and/or gastroesophageal reflux disease), renal impairment [estimated glomerular filtration rate (eGFR) ≥30 to <90 mL/minute], or mild, moderate, and severe hepatic impairment (Child-Pugh Class A-C) or fibrosis stage (F2 or F3 in patients with MASH).” (opens the source at this quote in a new tab)CopyFlag“The risk of renal adverse reactions with WEGOVY® was increased in adult patients with a history of renal impairment (trials included 65 patients with a history of moderate or severe renal impairment at baseline), and occurred more frequently during dose titration.” (opens the source at this quote in a new tab)CopyFlag“No limitations of use in patients with hepatic impairment” (opens the source at this quote in a new tab)CopyFlagOn the page, select: Pill